Amount of eligible individuals: CDEC talked about the uncertainty in the quantity of clients with moderately extreme to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some sufferers who will be labeled as obtaining gentle or moderate disease can have a critic